Levosulpiride for dyspepsia and emesis. A review of its pharmacology, efficacy and tolerability

G. R. Corazza, M. Tonini

Research output: Contribution to journalArticle

Abstract

Objective: To review the clinical pharmacology of levosulpiride and establish its efficacy and tolerability profile in the treatment of patients with dyspepsia and emesis. Methods: A critical review was conducted to assess the clinical pharmacology, therapeutic efficacy and tolerability of levosulpiride and to establish whether it offers any advantage over currently available therapies. Results: Levosulpiride has been evaluated in 15 double-blind, randomised clinical trials in patients with dyspepsia (n = 1818, of whom 676 were treated with levosulpiride) and 11 clinical trials in patients with emesis (n = 718, of whom 383 were treated with levosulpiride). It was shown to be effective in the treatment of dyspepsia (functional or organic dyspepsia, diabetic gastroparesis and reflux oesophagitis), the prevention and treatment of iatrogenic emesis resulting from pharmacological agents (anaesthetics, anticancer chemotherapy, calcitonin), and the treatment of severe non-iatrogenic nausea and vomiting. The incidence of adverse events was 11% in 840 patients with dyspepsia; most of them were mild and they resulted in treatment discontinuation in only eight (0.9%) cases. Conclusions: Levosulpiride should be considered among the drugs of choice for the treatment of various forms of dyspepsia and emesis.

Original languageEnglish
Pages (from-to)151-162
Number of pages12
JournalClinical Drug Investigation
Volume19
Issue number2
Publication statusPublished - 2000

Fingerprint

Dyspepsia
Vomiting
Pharmacology
Clinical Pharmacology
Therapeutics
Gastroparesis
Peptic Esophagitis
levosulpiride
Calcitonin
Antineoplastic Agents
Nausea
Anesthetics
Randomized Controlled Trials
Clinical Trials
Drug Therapy
Incidence
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology

Cite this

Levosulpiride for dyspepsia and emesis. A review of its pharmacology, efficacy and tolerability. / Corazza, G. R.; Tonini, M.

In: Clinical Drug Investigation, Vol. 19, No. 2, 2000, p. 151-162.

Research output: Contribution to journalArticle

@article{791c4f868de2435fa57e27321968216c,
title = "Levosulpiride for dyspepsia and emesis. A review of its pharmacology, efficacy and tolerability",
abstract = "Objective: To review the clinical pharmacology of levosulpiride and establish its efficacy and tolerability profile in the treatment of patients with dyspepsia and emesis. Methods: A critical review was conducted to assess the clinical pharmacology, therapeutic efficacy and tolerability of levosulpiride and to establish whether it offers any advantage over currently available therapies. Results: Levosulpiride has been evaluated in 15 double-blind, randomised clinical trials in patients with dyspepsia (n = 1818, of whom 676 were treated with levosulpiride) and 11 clinical trials in patients with emesis (n = 718, of whom 383 were treated with levosulpiride). It was shown to be effective in the treatment of dyspepsia (functional or organic dyspepsia, diabetic gastroparesis and reflux oesophagitis), the prevention and treatment of iatrogenic emesis resulting from pharmacological agents (anaesthetics, anticancer chemotherapy, calcitonin), and the treatment of severe non-iatrogenic nausea and vomiting. The incidence of adverse events was 11{\%} in 840 patients with dyspepsia; most of them were mild and they resulted in treatment discontinuation in only eight (0.9{\%}) cases. Conclusions: Levosulpiride should be considered among the drugs of choice for the treatment of various forms of dyspepsia and emesis.",
author = "Corazza, {G. R.} and M. Tonini",
year = "2000",
language = "English",
volume = "19",
pages = "151--162",
journal = "Clinical Drug Investigation",
issn = "1173-2563",
publisher = "Adis International Ltd",
number = "2",

}

TY - JOUR

T1 - Levosulpiride for dyspepsia and emesis. A review of its pharmacology, efficacy and tolerability

AU - Corazza, G. R.

AU - Tonini, M.

PY - 2000

Y1 - 2000

N2 - Objective: To review the clinical pharmacology of levosulpiride and establish its efficacy and tolerability profile in the treatment of patients with dyspepsia and emesis. Methods: A critical review was conducted to assess the clinical pharmacology, therapeutic efficacy and tolerability of levosulpiride and to establish whether it offers any advantage over currently available therapies. Results: Levosulpiride has been evaluated in 15 double-blind, randomised clinical trials in patients with dyspepsia (n = 1818, of whom 676 were treated with levosulpiride) and 11 clinical trials in patients with emesis (n = 718, of whom 383 were treated with levosulpiride). It was shown to be effective in the treatment of dyspepsia (functional or organic dyspepsia, diabetic gastroparesis and reflux oesophagitis), the prevention and treatment of iatrogenic emesis resulting from pharmacological agents (anaesthetics, anticancer chemotherapy, calcitonin), and the treatment of severe non-iatrogenic nausea and vomiting. The incidence of adverse events was 11% in 840 patients with dyspepsia; most of them were mild and they resulted in treatment discontinuation in only eight (0.9%) cases. Conclusions: Levosulpiride should be considered among the drugs of choice for the treatment of various forms of dyspepsia and emesis.

AB - Objective: To review the clinical pharmacology of levosulpiride and establish its efficacy and tolerability profile in the treatment of patients with dyspepsia and emesis. Methods: A critical review was conducted to assess the clinical pharmacology, therapeutic efficacy and tolerability of levosulpiride and to establish whether it offers any advantage over currently available therapies. Results: Levosulpiride has been evaluated in 15 double-blind, randomised clinical trials in patients with dyspepsia (n = 1818, of whom 676 were treated with levosulpiride) and 11 clinical trials in patients with emesis (n = 718, of whom 383 were treated with levosulpiride). It was shown to be effective in the treatment of dyspepsia (functional or organic dyspepsia, diabetic gastroparesis and reflux oesophagitis), the prevention and treatment of iatrogenic emesis resulting from pharmacological agents (anaesthetics, anticancer chemotherapy, calcitonin), and the treatment of severe non-iatrogenic nausea and vomiting. The incidence of adverse events was 11% in 840 patients with dyspepsia; most of them were mild and they resulted in treatment discontinuation in only eight (0.9%) cases. Conclusions: Levosulpiride should be considered among the drugs of choice for the treatment of various forms of dyspepsia and emesis.

UR - http://www.scopus.com/inward/record.url?scp=0034008407&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034008407&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0034008407

VL - 19

SP - 151

EP - 162

JO - Clinical Drug Investigation

JF - Clinical Drug Investigation

SN - 1173-2563

IS - 2

ER -